Fig. 1

Flow cytometry gating strategy of TRPM2 and CD38 using primary TRPM2 antibody (1:50) at 2 h/1 h. a Lymphocyte populations were identified using forward and side scatter dot plots. b Duration of cell acquirement was measured followed by (c) cell viability after 7-AAD staining. d CD3⁺ cells were excluded and only (e) CD3^- lymphocytes were further used to characterise NK cells by CD56. f CD3⁻/CD56⁺ NK cells were sorted into CD56^BrightCD16^Dim/− and CD56^Dim CD16⁺ NK cell subsets using CD56 and CD16. TRPM2 surface expression was measured on (g) CD56^Dim CD16⁺ and (h) CD56^BrightCD16^Dim/− NK cell subsets. Dual surface expression of TRPM2 and CD38 was furthermore assessed on (i) CD56^BrightCD16^Dim/− and (j) CD56^Dim CD16⁺ NK cell subsets